Want to continue the discussion? Send me a message.

We wait for a relapse, a missed stretch of pills, or a hospitalization, and only then the words “long-acting injectable” finally show up. I’m stepping back to ask a cleaner question for bipolar I disorder care: what needs to be true before an LAI earns a place in the conversation, not as a last resort, but as a thoughtfully explained option in maintenance treatment.

I walk through the difference between mentioning LAIs, considering them, and recommending them, because those are not the same moment clinically. We talk about why I introduce the option when a patient is stable and thriving on an oral medication, how psychoeducation reduces pressure, and why I don’t want anyone learning about injections for the first time during a crisis. From there, we get into a hard truth about mania: insight can drop while symptoms rise, and what feels “normal” internally can look dangerous externally. That distinction matters for relapse prevention planning and shared decision-making.

I also share what sticks with me after episodes end: patients may be clinically better but still recouping their lives, relationships, work, and public digital footprints. Finally, I unpack a case that exposes a common misunderstanding, when a patient assumes the injection replaces the rest of the treatment plan and quietly stops a key medication.